In further support of this, the aberrant expression of the IL-22 cognate receptor, interleukin-22 receptor 1 (IL-22R1), has been observed in many types of tumor, including lymphomas [13] and pancreatic [14], lung [15], and colon cancers [16]. Here, IL22 is linked to neoplasm.